Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fasiglifam + metformin
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Fasiglifam + metformin** is an investigational oral combination therapy evaluated for treatment of type 2 diabetes mellitus. Fasiglifam (TAK-875) is a small molecule agonist of G-protein-coupled receptor 40 (GPR40, also known as free fatty acid receptor 1, FFAR1), designed to enhance glucose-dependent insulin secretion without causing significant hypoglycemia or weight gain. Metformin is a well-established oral antihyperglycemic agent that primarily reduces hepatic glucose production and improves insulin sensitivity. The combination was studied to provide additive or synergistic effects for glycemic control. However, clinical development was terminated due to liver safety concerns with fasiglifam. The main developer was Takeda.
- Other names
- fasiglifam + metforminTAK-875 + metformin
02
Targets
FFAR1 (Free fatty acid receptor 1)AMPK (Adenosine monophosphate–activated protein kinase)GPD2 (Glycerol-3-phosphate dehydrogenase 2)
Beyond the preview
Go deeper on fasiglifam + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fasiglifam + metformin.